|
1
|
Perkins ND: The diverse and complex roles
of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132.
2012.PubMed/NCBI
|
|
2
|
Aggarwal BB: Nuclear factor-kappaB: The
enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xia Y, Shen S and Verma IM: NF-κB, an
active player in human cancers. Cancer Immunol Res. 2:823–830.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bradford JW and Baldwin AS: IKK/nuclear
factor-kappaB and oncogenesis: Roles in tumor-initiating cells and
in the tumor microenvironment. Adv Cancer Res. 121:125–145. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chaturvedi MM, Sung B, Yadav VR, Kannappan
R and Aggarwal BB: NF-κB addiction and its role in cancer: ‘One
size does not fit all.’. Oncogene. 30:1615–1630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hinz M and Scheidereit C: The IκB kinase
complex in NF-κB regulation and beyond. EMBO Rep. 15:46–61. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hinz M, Arslan SÇ and Scheidereit C: It
takes two to tango: IκBs, the multifunctional partners of NF-κB.
Immunol Rev. 246:59–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karin M: How NF-kappaB is activated: The
role of the IkappaB kinase (IKK) complex. Oncogene. 18:6867–6874.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Werner SL, Barken D and Hoffmann A:
Stimulus specificity of gene expression programs determined by
temporal control of IKK activity. Science. 309:1857–1861. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O'Dea EL, Barken D, Peralta RQ, Tran KT,
Werner SL, Kearns JD, Levchenko A and Hoffmann A: A homeostatic
model of IkappaB metabolism to control constitutive NF-kappaB
activity. Mol Syst Biol. 3:1112007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Häcker H and Karin M: Is NF-kappaB2/p100 a
direct activator of programmed cell death? Cancer Cell. 2:431–433.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baud V and Karin M: Is NF-kappaB a good
target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov.
8:33–40. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Suzuki J, Ogawa M, Muto S, Itai A, Isobe
M, Hirata Y and Nagai R: Novel IkB kinase inhibitors for treatment
of nuclear factor-kB-related diseases. Expert Opin Investig Drugs.
20:395–405. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sánchez-Serrano I: Success in
translational research: Lessons from the development of bortezomib.
Nat Rev Drug Discov. 5:107–114. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li ZW, Chen H, Campbell RA, Bonavida B and
Berenson JR: NF-kappaB in the pathogenesis and treatment of
multiple myeloma. Curr Opin Hematol. 15:391–399. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gilmore TD: Multiple myeloma: Lusting for
NF-kappaB. Cancer Cell. 12:95–97. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Viatour P, Merville MP, Bours V and
Chariot A: Phosphorylation of NF-kappaB and IkappaB proteins:
Implications in cancer and inflammation. Trends Biochem Sci.
30:43–52. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Beg AA, Ruben SM, Scheinman RI, Haskill S,
Rosen CA and Baldwin AS Jr: I kappa B interacts with the nuclear
localization sequences of the subunits of NF-kappa B: A mechanism
for cytoplasmic retention. Genes Dev. 6:1899–1913. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ganchi PA, Sun SC, Greene WC and Ballard
DW: I kappa B/MAD-3 masks the nuclear localization signal of
NF-kappa B p65 and requires the transactivation domain to inhibit
NF-kappa B p65 DNA binding. Mol Biol Cell. 3:1339–1352. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Beg AA, Sha WC, Bronson RT and Baltimore
D: Constitutive NF-kappa B activation, enhanced granulopoiesis, and
neonatal lethality in I kappa B alpha-deficient mice. Genes Dev.
9:2736–2746. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Klement JF, Rice NR, Car BD, Abbondanzo
SJ, Powers GD, Bhatt PH, Chen CH, Rosen CA and Stewart CL:
IkappaBalpha deficiency results in a sustained NF-kappaB response
and severe widespread dermatitis in mice. Mol Cell Biol.
16:2341–2349. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hayden MS and Ghosh S: Signaling to
NF-kappaB. Genes Dev. 18:2195–2224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bredel M, Scholtens DM, Yadav AK, Alvarez
AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, et
al: NFKBIA deletion in glioblastomas. N Engl J Med. 364:627–637.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rinkenbaugh AL and Baldwin AS: Monoallelic
deletion of NFKBIA in glioblastoma: When less is more. Cancer Cell.
19:163–165. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jungnickel B, Staratschek-Jox A,
Bräuninger A, Spieker T, Wolf J, Diehl V, Hansmann ML, Rajewsky K
and Küppers R: Clonal deleterious mutations in the IkappaBalpha
gene in the malignant cells in Hodgkin's lymphoma. J Exp Med.
191:395–402. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Furukawa M, Soh J, Yamamoto H, Ichimura K,
Shien K, Maki Y, Muraoka T, Tanaka N, Ueno T, Asano H, et al:
Silenced expression of NFKBIA in lung adenocarcinoma patients with
a never-smoking history. Acta Med Okayama. 67:19–24.
2013.PubMed/NCBI
|
|
27
|
Gasparini C, Celeghini C, Monasta L and
Zauli G: NF-κB pathways in hematological malignancies. Cell Mol
Life Sci. 71:2083–2102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guzman ML, Neering SJ, Upchurch D, Grimes
B, Howard DS, Rizzieri DA, Luger SM and Jordan CT: Nuclear
factor-kappaB is constitutively activated in primitive human acute
myelogenous leukemia cells. Blood. 98:2301–2307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guzman ML, Swiderski CF, Howard DS, Grimes
BA, Rossi RM, Szilvassy SJ and Jordan CT: Preferential induction of
apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci
USA. 99:16220–16225. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Morotti A, Parvis G, Cilloni D, Familiari
U, Pautasso M, Bosa M, Messa F, Arruga F, Defilippi I, Catalano R,
et al: CD7/CD56-positive acute myeloid leukemias are characterized
by constitutive phosphorylation of the NF-kB subunit p65 at Ser536.
Leukemia. 21:1305–1306. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Carrà G, Torti D, Crivellaro S, Panuzzo C,
Taulli R, Cilloni D, Guerrasio A, Saglio G and Morotti A: The
BCR-ABL/NF-κB signal transduction network: A long lasting
relationship in Philadelphia positive Leukemias. Oncotarget. Aug
22–2016.(Epub ahead of print). View Article : Google Scholar
|
|
32
|
Hsieh MY and Van Etten RA: IKK-dependent
activation of NF-κB contributes to myeloid and lymphoid
leukemogenesis by BCR-ABL1. Blood. 123:2401–2411. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Crivellaro S, Panuzzo C, Carrà G, Volpengo
A, Crasto F, Gottardi E, Familiari U, Papotti M, Torti D, Piazza R,
et al: Non genomic loss of function of tumor suppressors in CML:
BCR-ABL promotes IκBα mediated p53 nuclear exclusion. Oncotarget.
6:25217–25225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Apperley JF: Chronic myeloid leukaemia.
Lancet. 385:1447–1459. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Morotti A, Fava C and Saglio G: Milestones
and monitoring. Curr Hematol Malig Rep. 10:167–172. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Morotti A, Panuzzo C, Fava C and Saglio G:
Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid
leukemia. Expert Opin Biol Ther. 14:287–299. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chang NS: The non-ankyrin C terminus of
Ikappa Balpha physically interacts with p53 in vivo and dissociates
in response to apoptotic stress, hypoxia, DNA damage, and
transforming growth factor-beta 1-mediated growth suppression. J
Biol Chem. 277:10323–10331. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dreyfus DH, Nagasawa M, Gelfand EW and
Ghoda LY: Modulation of p53 activity by IkappaBalpha: Evidence
suggesting a common phylogeny between NF-kappaB and p53
transcription factors. BMC Immunol. 6:122005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li X, Xing D, Wang J, Zhu DB, Zhang L,
Chen XJ, Sun FY and Hong A: Effects of IkappaBalpha and its mutants
on NF-kappaB and p53 signaling pathways. World J Gastroenterol.
12:6658–6664. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou M, Gu L, Zhu N, Woods WG and Findley
HW: Transfection of a dominant-negative mutant NF-kB inhibitor
(IkBm) represses p53-dependent apoptosis in acute lymphoblastic
leukemia cells: Interaction of IkBm and p53. Oncogene.
22:8137–8144. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Correia NC, Gírio A, Antunes I, Martins LR
and Barata JT: The multiple layers of non-genetic regulation of
PTEN tumour suppressor activity. Eur J Cancer. 50:216–225. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Leslie NR and Foti M: Non-genomic loss of
PTEN function in cancer: Not in my genes. Trends Pharmacol Sci.
32:131–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Morotti A, Panuzzo C, Crivellaro S,
Pergolizzi B, Familiari U, Berger AH, Saglio G and Pandolfi PP:
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through
phosphorylation-dependent activation of HAUSP. Leukemia.
28:1326–1333. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Morotti A, Panuzzo C, Crivellaro S, Carrà
G, Fava C, Guerrasio A, Pandolfi PP and Saglio G: BCR-ABL
inactivates cytosolic PTEN through Casein Kinase II mediated tail
phosphorylation. Cell Cycle. 14:973–979. 2015. View Article : Google Scholar : PubMed/NCBI
|
